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Objective. This article compares judgments about the treatment of Dukes' B2 and C
colon cancer made by general surgeons to those of internists and family practitioners.
Physician and practice variables were specialty, affiliation with a Community Clinical
Oncology Program (CCOP) hospital, time in practice, professional centrality (level
of participation in cancer information networks), solo practice, and number of colon
cancer patients.
Data Collection Methods. Data are combined from national probability samples of
CCOP- and non-CCOP-affiliated physicians. This study focused on 1,138 internists,
family physicians, and general surgeons who participated in decision making for
patients diagnosed with Dukes' B2 or C stage colon cancer.Judgments were elicited
using brief vignettes.
Methods of Analysis. Judgments of adjuvant therapy are classified as (a) consis-
tent with the National Institutes of Health Consensus Conference recommendations
(experimental for Dukes' B2, accepted for Dukes' C); (b) accepted treatment for both
stages; or (c) experimental for both stages. Multinomial logit analyses were used to
examine the association of practice setting and physician characteristics to judgments
of treatment.
Results. Surgeons and CCOP-affiliated physicians were more likely to endorse the
NIH consensus conference position. Surgeons, younger physicians, and those in group
practice were more likely to approve ofchemotherapy for both cancer stages. The most
common position (chemotherapy experimental) was more likely from nonsurgeons,
solo practitioners, and non-CCOP physicians.
Conclusion. Physician and practice setting characteristics, including organized struc-
tures such as the CCOP, are possible mediating structures that can facilitate dissemi-
nation of standards of treatment.
Key Words. Colonic neoplasms, therapy; practice characteristics; medical decision
making
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Colorectal cancer, a major public health problem in the United States, is
the second most common cancer and in cancer mortality is surpassed only
by lung cancer (Garfinkel 1991). The primary treatment is surgery, with
more than 80 percent of patients operable at the time of diagnosis (Moertel,
Fleming, MacDonald, et al. 1990; Sugarbaker 1986). The overall five-year
rate of survival is about 50 percent for African Americans, and 60 percent
for whites (Miller, Ries, and Hankey 1994; Chu, Tarone, Chow, et al. 1994).
However, survival is strongly influenced by disease stage: the survival rate is
as high as 90 percent for local disease and 60 percent for regional disease, but
only 7 percent for distant disease (Miller, Ries, and Hankey 1994).
This article compares the judgments of colon cancer treatments made
by general surgeons to judgments by internists and family practitioners. We
examine the medical decision making of community physicians for two rea-
sons. First, community physicians have a prominent role in the treatment of
this prevalent cancer, either directly or through referral. In this study, commu-
nity physicians are physicians who are not oncologists or hematologists, but
include family practitioners, internists, and general surgeons. Since 80 percent
of all cancer is treated in local communities and substantial proportions
of primary care physicians report participating in treatment decision mak-
ing, factors influencing the judgments of primary care physicians are critical
(Kaluzny, Ricketts, Warnecke, et al. 1989). We examine medical decision
making in relation to this condition because the dynamic nature oftechnology
has led to the accumulation ofevidence that points to the potential ofadjuvant
treatments for colorectal cancer.
A consensus conference on adjuvant therapy for colon and rectum
cancer was held in 1990 (National Institutes ofHealth 1990). Such conferences
are called when the belief is growing (not always well founded) that sufficient
evidence exists to lead to the emergence ofconsensual positions to guide prac-
tice and research. The consensus development process is intended to assist
in the timely and appropriate application of research findings into medical
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practice (National Institute of Medicine, Council on Health Care Technology
1990). The judgments of physicians, which are the focus of this study, were
gathered shortly before the consensus conference met, as part of a larger
evaluation of the Community Clinical Oncology Program (CCOP). While
the timing of data collection is not ideal for this article, the CCOP evaluation
data permit examination of physician judgments in a time of considerable
uncertainty about the relative role ofwholly surgical and adjuvant therapeutic
approaches.
Studies evaluating adjuvant treatment of colon cancer have been taking
place for about 30 years. With respect to methodology, studies have become
increasingly attentive to issues ofinternal validity, with greater use ofrandom-
ized studies; precision in the description of the tumor, the tumor's location,
and staging; and the use of larger samples in order to examine subgroups and
enhance statistical power (Buyse, Zeleniuch-Jacquotte, and Chalmers 1988;
Gilbert 1986; Ajani 1988).
The 1990 consensus conference was called to determine the status of
adjuvant therapies for colon and rectal cancer following several studies finding
improved survival. The purpose of a consensus conference is to assess data
and come to a conclusion (consensus) that a treatment is clearly accepted or
remains experimental, that is in need of further study. The consensus con-
ference recommended that Dukes' A (Dukes 1956) or Stage 11 colon cancer
patients should be treated with surgery alone because of its favorable survival
rate. Patients with Dukes' C (Stage 3) colon cancer were recommended to be
treated with adjuvant therapy. The consensus panel did not recommend any
specific adjuvant therapy for Dukes' B2 (Stage 2) patients outside of clinical
trials. Continued clinical trials to assess adjuvant therapies were encouraged
for both colon and rectal cancer.
The objectives of this study are to (1) assess the extent of agreement
among primary care physicians with the current treatment options for colon
and rectal cancer, and (2) examine physician and practice setting character-
istics associated with assessment of adjuvant therapy for two different stages
of colon cancer.
Characteristics ofPhysicians and Practice Settings
This research was guided by literature on medical decision making and the
adoption of medical and surgical innovations such as procedures, drugs, and
other technologies. Our prior research on physician judgments of treatment
for breast cancer was also useful (McFall, Warnecke, Kaluzny, et al. 1994).
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Several physician and practice setting characteristics are hypothesized
to influence judgments of treatments. Specialty is expected to be influential
in judgments (Grilli, Apolone, Marsoni, et al. 1991). Surgical oncology has
been a leading specialty in both the development of treatment protocols and
the conduct of clinical trials for colon cancer. Therefore, we expect surgeons
to be more aware of current practice patterns.
An additional physician characteristic expected to be influential is the
length of time in practice. The period in which a physician receives basic
training, or correspondingly, the length of time since graduation, influences
the adoption ofnew procedures (Freiman 1985). Physicians in practice longer
are shaped by their practices andjudgments made during their period oftrain-
ing and early practice. Our prior research found older physicians less likely
to be in agreement with the consensus conference position on treatment of
breast cancer (McFall, Warnecke, Kaluzny, et al. 1994). Older physicians have
also been found more likely to hospitalize patients for conditions commonly
treated on an outpatient basis (Siu, Manning, and Benjamin 1990). Length of
time in practice is most likely to be influential in practice areas experiencing
rapid change.
Practice setting shapes the informal and formal opportunities to discuss
and observe different treatment alternatives. Physicians who practice alone
are less likely to be aware ofnew information regarding patient care (Freiman
1985) and physicians in rural, solo practices are less likely to adopt new
procedures (Coleman, Katz, and Menzel 1966). Thus, we hypothesize that
physicians in solo practice will be less aware of the utility of new practice
patterns.
Physicians also differ in their access to information concerning practice
guidelines and evidence from clinical trials. We hypothesize that physicians
participating in networks that disseminate information about cancer treatment
and research will be better informed about treatment options than physicians
who do not participate in such information networks (McFall, Warnecke,
Kaluzny, et al. 1994; Grilli, Apolone, Marsoni, et al. 1991). We refer to level
of participation in dissemination networks as professional centrality.
Affiliation with the CCOP is a particular example of participation in
a dissemination network. One purpose of the CCOP networks, which were
initiated in 1981, is to provide community-based physicians with access to
state-of-the-art information about the treatnent and prevention of cancer
(Kaluzny, Lacey, Warnecke, et al. 1994; Kaluzny, Warnecke, Lacey, et al.
1995). Physicians affiliated with CCOP hospitals may have greater access
than other physicians to current information about the treatment of colon
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cancer. Prior studies found that CCOP physicians were early innovators in
recommending chemotherapy for Stage I breast cancer (McFall, Warnecke,
Kaluzny, et al. 1994).
An adequate patient volume has been linked to acceptable performance
of hospital units and individual physicians (Jollis, Peterson, DeLong, et al.
1994). Physicians with greater experience in treating a particular condition
have been shown to be more aware of treatment guidelines than their less-
experienced counterparts. Thus, we hypothesize that number of colon cancer
patients will influence the treatment judgments of physicians.
METHODS
SAMPLE DESIGN AND EXECUTION
These data were collected in a national survey of physicians, conducted as
part of the evaluation of the National Cancer Institute's Community Clinical
Oncology Program (CCOP-I1) (Kaluzny, Warnecke, and Gillings 1992). This
survey of physicians in four primary care specialties (family practice, internal
medicine, gynecology, and general surgery) was designed to obtain informa-
tion on community physicians' knowledge and attitudes about cancer patient
management and to assess whether the presence of the CCOP influenced the
attitudes and self-reported practices of physicians in the community regard-
ing cancer treatment and screening. Other components of the evaluation
examined treatment patterns using medical record review. The project was
reviewed and approved by the institutional review boards at the University
of North Carolina at Chapel Hill and the University of Illinois at Chicago.
Two samples ofphysicians were selected. The CCOP community physi-
cians were a stratified, systematic random sample of physicians in the four
designated specialties who had admitting privileges atCCOP component hos-
pitals, but who were neither oncologists nor hematologists. The other sample
of community physicians was a stratified, systematic random sample drawn
from the American Medical Association's (AMA) listing of physicians in all
50 states and Puerto Rico in the four designated specialties with admitting
privileges at hospitals not affiliated with a CCOP. In selecting both samples,
the goal was to obtain representative samples of community physicians who
might identify, initially diagnose, and refer adult cancer patients, but who did
not specialize in oncology or hematology.
Interviews were conducted between October 2, 1989 and March 31,
1990. A brief telephone screening interview verified eligibility. The initial
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sample of CCOP community physicians included 3,136 physicians and the
initial non-CCOP sample consisted of 2,879 physicians. After screening, 481
CCOP community physicians and 428 non-CCOP physicians were ineligible
because of specialty; because they had retired, died, or did not treat adults; or,
in the case of the CCOP sample, because they were no longer affiliated with a
CCOP hospital. The final eligible samples included 2,655 CCOP community
physicians and 2,451 non-CCOP physicians. Interviews were completed with
1,898 (71 percent) physicians in the eligible CCOP sample and 1,538 (63
percent) in the eligible non-CCOP sample. By specialty, completion rates
ranged from 67 percent to 77 percent for the non-CCOP andCCOP surgeons
and gynecologists, and the CCOP family physicians. Completion rates were
52 percent to 59 percent for the non-CCOP and CCOP internists, and the
non-CCOP family practitioners.
For this study the sample was further restricted by excluding gynecolo-
gists, since relatively few had patients with colorectal cancer. Then, the sample
was limited to physicians who had seen patients diagnosed with Dukes' B2- or
C-stage colon or rectal cancer in the past year and who reported participating
in decision making about the patients' treatment The analysis is thus limited
to 1,138 physicians who were actively involved in treatment and referral
decisions. The AMA and CCOP samples were combined because they were
similar in physician and practice setting characteristics and in judgments of
treatnent options.
MEASUREMENT
Mini-vignettes were used to assess physician opinions about treatment for
Dukes' B2- or C-stage colon cancer and rectal cancer. The question wording
was
"Listed below are procedures for the treatment of Dukes' B2 colon cancer.
For each one, do you consider it to be experimental, an accepted or common
practice, outmoded or never appropriate treatment?"
Parallel wording was used for items dealing with treatment of Dukes' C
colon cancer. The specific treatments were
1. Surgery alone for (Dukes' B2, Dukes' C) colon cancer, or
2. Surgery followed by adjuvant multidrug chemotherapy for (Dukes'
B2, Dukes' C) colon cancer.
We have focused in this study on the two items that address judgments
of surgery with adjuvant multidrug chemotherapy for Dukes' B2 and Dukes'
C colon cancer.
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Several physician and practice setting characteristics were examined.
For specialty, family practitioners and internists were combined to represent
nonsurgeons, with general surgeons representing the reference category.2
CCOP affiliation was a dichotomous variable with CCOP physicians coded
"1." "Years in practice" assigned a code "1" to those who graduated from
medical school 20 or more years before the study; all other options were
coded "0," the reference category. We also examined this variable coded
continuously and classified as 1-9 years, 10-19 years, and 20 years or more.
The judgments of physicians practicing longer than 20 years were the most
distinctive, so we contrasted that group with physicians practicing 19 years
or fewer.
"Practice setting" was a single dichotomous variable with those in solo
private practice coded as "1"; those in a group practice, in a two-physician
private practice, or in other settings were the reference category, coded "0."
Professional centrality assessed whether physicians participated in infor-
mation networks about cancer treatment and research. Professional centrality
was indicated by four variables. The first three included (a) referral or direct
enrollment of patients in clinical trials in the past year, (b) membership or
participation in a professional association concerned with cancer research
or treatment, and (c) completion of continuing education or other seminars
in oncology or cancer care in the past two years. The fourth indicator was
awareness of the Physician Data Query (PDQ) system. The PDQis a cancer
database of the National Cancer Institute that includes information about
investigative cancer treatments, a directory of oncologists, and a listing of
clinical trials with patient openings. We classified as high on centrality physi-
cians with a positive response on any two of the four indicators.
Physicians reported the number ofpatients diagnosed with colon cancer
in the past year.A square-root transformation was used to reduce the skewness
of this variable.
ANALYSIS
We present descriptive information on characteristics of the analysis sample.
We next show the physician rating of adjuvant chemotherapy for the two
cancer stages by specialty group. Physician judgments are presented for four
categories:
1. Dukes' B2 experimental, Dukes' C accepted practice, or the NIH
position;
2. Accepted practice for both cancer stages or premature adoption of
chemotherapy for less invasive cancers;
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3. Experimental for both cancer stages, which is the most conservative
position; and
4. Some other response.
A small proportion of physicians (less than 10 percent overall) had the last
response pattern and were not included in the multivariate analyses.
We use multinomial logit analysis to assess the effect of physician and
practice setting characteristics on physicianjudgments about adjuvant chemo-
therapy for colon cancer. In multinomial logit analyses with dependent vari-
ables having three categories, there are two sets of coefficients corresponding
to specific contrasts among categories of the dependent variable. In this
article we contrast physicians recommending the NIH consensus conference
position to those rating chemotherapy as experimental and to those rating it as
accepted practice for both stages. The results of these analyses are expressed
as adjusted odds ratios with 95 percent confidence intervals.
RESULTS
Table 1 presents the percentage of physicians, by specialty, who reported
seeing patients with colon cancer in the past year and the percentage of that
group who participated in decision making about the surgical or nonsurgical
treatment of the patients. General surgeons were highly likely (79.6 percent)
to see patients diagnosed with colon cancer, while fewer than half of the non-
surgeons had patients with this condition. Virtually all general surgeons with
colorectal cancer patients reported participating in decision making about
treatment, and more than half of nonsurgeons also participated in decision
making beyond referral of the patient. The remainder of the analysis was
conducted on the subset of physicians who participated in decision making.
Surgeons differed from nonsurgeons on several of the characteristics
examined. The former, for example, were more likely to be in solo practice
and to have been in practice for more than 20 years than the nonsurgeons.
The general surgeons also scored higher on professional centrality and had a
greater volume of colon cancer patients.
JUDGMENTS ABOUT TREATMENT AND SPECIALTY
Figure 1 shows the judgments of surgeons and nonsurgeons of adjuvant
chemotherapy for Dukes' B2 and C colon cancer, jointly considered. The
modal response for both surgeons (38 percent) and nonsurgeons (50 percent)
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Table 1: Percentage of Physicians with Colorectal Cancer Patients,




Colon cancer patients, past year 44.1% 79.6%
Rectal cancer patients, past year 23.1% 67.1%
N 1487 950
OfThose with Patients:




Solo practice 38.4% 48.1%
Time in practice (20 years +) 39.8% 60.9%
Professional centrality (High) 33.8% 65.8%
Mean number colon cancer patients 4.0 10.2
(s.d.) (6.0) (9.5)
N 395 742
was that adjuvant therapy was experimental for both cancer stages. Twenty-
two percent ofnonsurgeons and 29 percent ofsurgeons rated adjuvant therapy
as common/accepted practice for both stages. The NIH consensus conference
position (experimental for Dukes' B2 and accepted practice for Dukes' C
colon cancer) was selected by 16 percent of nonsurgeons and 24 percent of
surgeons. The responses of about 10 percent of physicians did not fall into
these three categories.
MULTIVARIATE ANALYSES
We conducted multinomial logit analyses to examine the effect of physician
and practice setting characteristics on the selection of the three alternatives.
The significant predictors were specialty, solo practice, and time in practice.
The variable describing whether the physician was affiliated with a CCOP
hospital was of borderline statistical significance (p = .056). Table 2 presents
the results of these analyses. The first column contrasts the selection of the
NIH position relative to rating adjuvant therapy as experimental for both
stages. The second column compares the selection of the NIH position rela-
tive to the acceptance of adjuvant therapy for both stages.
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Figure 1: Physician Ratings of Colon Cancer Treatment for Dukes'
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Consensus Conference Position versus
Experimentalfor Both Stages
General surgeons were two times more likely than nonsurgeons to select the
consensus conference position than to view adjuvant therapy as experimen-
tal. CCOP-affiliated physicians were more likely to select the NIH position
than to view adjuvant therapy as experimental. That is, CCOP-affiliated
physicians were slightly more likely than non-CCOP physicians to pick the
NIH position (23 percent versus 19 percent), and 47 percent of non-CCOP
physicians judged adjuvant therapy experimental compared to 39 percent
of the CCOP-affiliated physicians. The distinction between solo and group
or small group practice was significantly linked to physician judgments (p =
.0002). However, the individual contrasts between the NIH position and the
other two alternatives were ofborderline significance based on the Wald tests.
The chief distinction is that solo practitioners were more likely than those in
group practice to view chemotherapy as experimental for both stages (49
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Table 2: PhysicianJudgments of Adjuvant Chemotherapy for Dukes'
B2 and Dukes' C Colon Cancer (Adjusted Odds Ratios and 95%
Confidence Intervals)
NIH Position versus NIHPosition versus
Experimental Treatment Accepted Practice
95% 95%
Odds Confidence Odds Confidenc
Variable Ratio Interval Ratio Interval
General surgery 2.18 1.52-3.12 1.02 0.68-1.52
CCOP* affiliation 1.45 1.05-2.00 1.13 0.80-1.61
Time in practice 0.92 0.66-1.28 1.47 1.02-2.10
Solo practice 0.73 0.53-1.02 1.42 0.99-2.05
*Community Clinical Oncology Program.
percent versus 37 percent), but they were about equally likely to endorse the
NIH position. Time in practice was not associated with this comparison.
Consensus Conference Position versus Acceptedfor Both Stages
Time in practice was influential for this comparison. Older physicians were
more likely than younger physicians to select the NIH position relative to
viewing chemotherapy as accepted practice, but did not differ in contrasting
the NIH and experimental positions. In examining the proportions, young
and old physicians were equally likely to select the NIH position (22 percent
versus 20 percent). However, younger physicians were more likely than older
physicians to rate chemotherapy as an accepted treatment for both cancer
stages (32 percent versus 22 percent). Similarly, solo and non-solo practice
physicians did not differ in selecting the NIH position (21 percent each); but
the non-solo physicians were more likely to view chemotherapy as accepted
practice (32 percent versus 20 percent). Specialty and CCOP affiliation were
not associated with this comparison.
Analyses using a simple dichotomous coding (consistent with the NIH
position versus otherjudgments) were also conducted. The only variable with
a significant relationship to that outcome was specialty. More surgeons had
judgments consistent with the NIH position. The multinomial logit analyses
pernitted us to distinguish practice and physician characteristics associated
with different directions of divergence from the NIH position.
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DISCUSSION
In this study we examined characteristics of primary care physicians and
practice settings associated with judgments of treatment options for colon
cancer. The sample was restricted to physicians participating in treatment
decisions, from whom we could expect a more direct interest in cancer
treatment.
The physicians' judgments of treatments were made about the time
of the NIH consensus conference on the use of adjuvant therapy for colon
cancer. The consensus conference recommended adjuvant chemotherapy for
Dukes' C, but not for Dukes' B2 colon cancer. We classified physician views
as consistent with the NIH position, common/accepted practice for both
stages (premature acceptance of chemotherapy for less invasive cancer), or
experimental for both stages. The last position is a conservative one that
lags behind the NIH position. One potential use of this information is to
describe the distribution of these judgments. Clearly, the dominant position
among both surgeons and nonsurgeons is that adjuvant chemotherapy is
an experimental treatment. Dissemination efforts must convey the evidence
supporting the benefits of adjuvant therapy for enhancing survival time of
patients with Dukes' C colon cancer.
The study also permits us to examine physician and practice setting
characteristics associated with judgments of chemotherapy for colon cancer.
Those in agreement with the consensus conference position can be viewed as
early adopters. The early adopters in the study were more likely to be surgeons
or affiliated with a CCOP. Other physicians approved of chemotherapy
in both cancer stages, a pattern of premature acceptance of chemotherapy
for less invasive tumors. They may have been aware of the usefulness of
chemotherapy in some situations and then "guessed" or overgeneralized
these benefits to the treatment of both cancer stages in advance of the sci-
entific evidence. This position was more common among surgeons, younger
physicians, and those in group practice. These groups have been found to
be more aware of state-of-the-art treatment (McFall, Warnecke, Kaluzny, et
al. 1994), and this awareness is shown in judgments of colon cancer as well.
However, the awareness of the utility of adjuvant chemotherapy was not
precisely targeted. Dissemination efforts must clarify the importance ofcancer
stage for judgments of treatments. The third and largest group of physicians
rated chemotherapy as experimental for both cancer stages. This position
was more common among nonsurgeons, solo practitioners, and physicians
without an affiliation with CCOP. This group is poised in a position that
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may for the moment be satisfactory; yet, with the passage of a little time, it
will leave them as late adopters of therapeutic approaches associated with
improved survival.
These findings bear on structures that reinforce quality of care. Com-
munication with other physicians is important in shaping judgments and is
enhanced by practicing in the company of others or by being more central,
that is, having greater participation in information networks. Practice setting,
information networks, and organized structures such as the CCOP are possi-
ble mediating structures that can facilitate communication about standards of
treatment (Kaluzny, Warnecke, Lacey, et al. 1995). Affiliation with a CCOP
hospital was found consistent with a newly advanced state-of-the-art treatment
in both colon and breast cancer (McFall, Warnecke, Kaluzny, et al. 1994).
Communities in which treatment is providedby primary care physicians
rather than oncologists represent a special challenge. Failure to address the
challenge of linking physicians to advancing technology will limit the ability
of local communities to benefit from therapeutic developments.
NOTES
1. Several staging methods are available. The Dukes classification is based on depth
of tumor invasion into the bowel wall. It has a long history of use and has been
criticized because revisions have reduced its clarity. A rough correspondence can
be made between the Dukes and the Tumor, Node, Metastases (T,N,M) methods.
We used the Dukes system because we believed that more community physicians
would be familiar with the ramifications for treatment of the various Dukes' stages.
Dukes' B2 would be included in Stage II based on the T,N,M system, and Dukes'
C would be included in Stage III.
2. Alternative analyses contrasting each specialty with that of general surgery pro-
duced similar results.
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